Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
Crossref DOI link: https://doi.org/10.1186/s13045-016-0367-x
Published Online: 2016-12-08
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Verstovsek, Srdan
Odenike, Olatoyosi
Singer, Jack W.
Granston, Tanya
Al-Fayoumi, Suliman
Deeg, H. Joachim
Funding for this research was provided by:
CTI BioPharma Corp
